Noteworthy Price Action: PhotoMedex Inc Has Another Very Strong Trading Session

Noteworthy Price Action: PhotoMedex Inc Has Another Very Strong Trading Session

The stock of PhotoMedex Inc (NASDAQ:PHMD) is a huge mover today! The stock increased 46.15% or $0.78 during the last trading session, hitting $2.47. About 647,847 shares traded hands or 1130.50% up from the average. PhotoMedex Inc (NASDAQ:PHMD) has declined 11.05% since April 22, 2016 and is downtrending. It has underperformed by 16.46% the S&P500.
The move comes after 5 months positive chart setup for the $11.52M company. It was reported on Nov, 25 by Barchart.com. We have $2.57 PT which if reached, will make NASDAQ:PHMD worth $460,800 more.

According to Zacks Investment Research, “Photomedex, Inc. develops, manufactures and markets therapeutic excimer laser-based instrumentation designed to treat psoriasis and vitiligo. They are also developing their technology for the treatment of other skin disorders. They’ve received the first Food and Drug Administration, or FDA, approval to market an excimer laser system, XTRAC system, for the treatment of psoriasis. They have commercially launched the XTRAC system in the United States.”

Insitutional Activity: The institutional sentiment decreased to 0.04 in Q2 2016. Its down 0.56, from 0.6 in 2016Q1. The ratio turned negative, as 9 funds sold all PhotoMedex Inc shares owned while 6 reduced positions. 4 funds bought stakes while 5 increased positions. They now own 2.91 million shares or 39.23% less from 4.79 million shares in 2016Q1.
Focused Wealth Mgmt reported 12,962 shares or 0% of all its holdings. Bankshares Of New York Mellon accumulated 0% or 63,486 shares. Jpmorgan Chase & last reported 803 shares in the company. California Employees Retirement Systems last reported 41,600 shares in the company. Jane Street Gp Ltd Liability Com has 20,499 shares for 0% of their US portfolio. Geode Cap Mgmt Limited Liability Com holds 0% or 73,448 shares in its portfolio. Northern Tru owns 47,700 shares or 0% of their US portfolio. Stevens First Principles Invest reported 1,047 shares or 0% of all its holdings. Blackrock Fund Advisors has 0% invested in the company for 2,484 shares. Manufacturers Life The accumulated 0% or 575 shares. Carroll Financial Assocs Inc accumulated 2 shares or 0% of the stock. The Illinois-based Citadel Advsr Ltd Limited Liability Company has invested 0% in PhotoMedex Inc (NASDAQ:PHMD). Ladenburg Thalmann Fincl Svcs has invested 0% of its portfolio in PhotoMedex Inc (NASDAQ:PHMD). The Kansas-based Creative Planning has invested 0% in PhotoMedex Inc (NASDAQ:PHMD). Kcg Hldgs Inc, a New Jersey-based fund reported 14,356 shares.

Another recent and important PhotoMedex Inc (NASDAQ:PHMD) news was published by Globenewswire.com which published an article titled: “MELA Sciences Acquires XTRAC and VTRAC Businesses From PhotoMedex, Inc.” on June 23, 2015.

PHMD Company Profile

PhotoMedex, Inc., incorporated on December 28, 2010, is a global health services and products firm providing integrated disease management and solutions to dermatologists, professional aestheticians and consumers. The Firm provides services and products that address skin diseases and conditions, including acne and photo damage. It operates through three business divisions: Consumer segment, Physician Recurring segment and Professional segment. It provides skin health solutions to spa markets, as well as traditional retail, online and infomercial outlets for home-use products. Through its subsidiary, Radiancy, Inc., it offers a range of home-use devices under the no!no! brand, for various indications, including hair removal, acne treatment, skin rejuvenation and lower back pain. In addition, its professional product line includes offerings for acne clearance, skin tightening, psoriasis care and hair removal sold to physician clinics and spas. The Firm is also engaged in the development, manufacture and sale of surgical products, including free-beam and Contact Laser Systems for surgery.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment